Close Menu

NEW YORK – The past few years have seen a significant shift in payor attitudes toward liquid biopsy cancer testing, including recent growth in the number of positive coverage policies and a shift toward pan-cancer versus cancer-specific implementation, a new study published this Monday has found.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.